Xu C, Chen S, Chen X, Ho K, Park C, Yoo H
Front Mol Neurosci. 2023; 16:1175522.
PMID: 37664244
PMC: 10470468.
DOI: 10.3389/fnmol.2023.1175522.
Dulanto J, Chu D, Saffari P, Abdelshahid M, Xu P, Hauser J
Cureus. 2023; 15(3):e35666.
PMID: 36875252
PMC: 9981230.
DOI: 10.7759/cureus.35666.
Serranilla M, Woodin M
Front Cell Neurosci. 2022; 15:817013.
PMID: 35095429
PMC: 8795088.
DOI: 10.3389/fncel.2021.817013.
Frank W, Lindenberg K, Muhlback A, Lewerenz J, Landwehrmeyer G
Nervenarzt. 2021; 93(2):179-190.
PMID: 34762178
PMC: 8825394.
DOI: 10.1007/s00115-021-01224-8.
Matsuhashi T, Segalowitz S, Murphy T, Nagano Y, Hirao T, Masaki H
Psychophysiology. 2020; 58(1):e13708.
PMID: 33111987
PMC: 7816271.
DOI: 10.1111/psyp.13708.
The Discovery and Characterization of Targeted Perikaryal-Specific Brain Lesions With Excitotoxins.
Coyle J, Schwarcz R
Front Neurosci. 2020; 14:927.
PMID: 33013307
PMC: 7509407.
DOI: 10.3389/fnins.2020.00927.
EGF Treatment Improves Motor Behavior and Cortical GABAergic Function in the R6/2 Mouse Model of Huntington's Disease.
Marottoli F, Priego M, Flores-Barrera E, Pisharody R, Zaldua S, Fan K
Mol Neurobiol. 2019; 56(11):7708-7718.
PMID: 31104296
PMC: 6815691.
DOI: 10.1007/s12035-019-1634-y.
Insights into GABAergic system alteration in Huntington's disease.
Hsu Y, Chang Y, Chern Y
Open Biol. 2018; 8(12).
PMID: 30518638
PMC: 6303784.
DOI: 10.1098/rsob.180165.
Huntington's disease: the coming of age.
Pandey M, Rajamma U
J Genet. 2018; 97(3):649-664.
PMID: 30027901
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
Jamwal S, Kumar P
Curr Neuropharmacol. 2018; 17(2):165-175.
PMID: 29512464
PMC: 6343208.
DOI: 10.2174/1570159X16666180302115032.
Antioxidant capacity and amino acid profile of millet bran wine and the synergistic interaction between major polyphenols.
Guo X, Sha X, Rahman E, Wang Y, Ji B, Wu W
J Food Sci Technol. 2018; 55(3):1010-1020.
PMID: 29487443
PMC: 5821658.
DOI: 10.1007/s13197-017-3014-9.
Alteration of GABAergic neurotransmission in Huntington's disease.
Garret M, Du Z, Chazalon M, Cho Y, Baufreton J
CNS Neurosci Ther. 2018; 24(4):292-300.
PMID: 29464851
PMC: 6490108.
DOI: 10.1111/cns.12826.
Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice.
Sorolla M, Rodriguez-Colman M, Vall-Llaura N, Vived C, Fernandez-Nogales M, Lucas J
Metab Brain Dis. 2015; 31(3):579-86.
PMID: 26666246
DOI: 10.1007/s11011-015-9777-7.
Neurotransmitters as food supplements: the effects of GABA on brain and behavior.
Boonstra E, de Kleijn R, Colzato L, Alkemade A, Forstmann B, Nieuwenhuis S
Front Psychol. 2015; 6:1520.
PMID: 26500584
PMC: 4594160.
DOI: 10.3389/fpsyg.2015.01520.
Dexmedetomidine with low-dose ketamine for cataract surgery under peribulbar block in a patient with Huntington's chorea.
Naik S, Shetti A, Nadkarni A, Ahuja B
Anesth Essays Res. 2015; 9(1):92-4.
PMID: 25886428
PMC: 4383114.
DOI: 10.4103/0259-1162.150140.
Treatment of Huntington's disease.
Frank S
Neurotherapeutics. 2013; 11(1):153-60.
PMID: 24366610
PMC: 3899480.
DOI: 10.1007/s13311-013-0244-z.
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.
Frank S
Neuropsychiatr Dis Treat. 2010; 6:657-65.
PMID: 20957126
PMC: 2951749.
DOI: 10.2147/NDT.S6430.
Therapeutic Strategies in Huntington's Disease.
Kanazawa I
J Clin Neurol. 2010; 2(4):213-24.
PMID: 20396523
PMC: 2854970.
DOI: 10.3988/jcn.2006.2.4.213.
Advances in the pharmacological management of Huntington's disease.
Frank S, Jankovic J
Drugs. 2010; 70(5):561-71.
PMID: 20329804
DOI: 10.2165/11534430-000000000-00000.
Four decades of neurodegenerative disease research: how far we have come!.
Young A
J Neurosci. 2009; 29(41):12722-8.
PMID: 19828782
PMC: 2807668.
DOI: 10.1523/JNEUROSCI.3767-09.2009.
